Rodolfo Chicas-Sett
@OncoRod
Followers
586
Following
4K
Media
70
Statuses
2K
MD. MSc. PhD. Radiation Oncology - Immunotherapy. #Gastrointestinal & Lung Cancer #I-SABR unit #radonc 🇬🇹🇪🇸
Valencia, Spain
Joined January 2019
Our paper is out!!! #redjournal -Combination of SABR with immunotherapy in oligoprogressive patients in progression to anti-PD-1 -Multicenter study -FU: 32.8 m -Concurrent -35 Gy/5fx ✅ORR 42% ✅PFS 14.2 m ✅OS 37.4 m ✅✅ Safety @ZafraMD @delvysra
https://t.co/74pSImuXwk
1
9
23
If you haven’t heard yet #radonc - courtesy of Snr Ortega, owner/founder of @ZARA, 🇪🇸 is receiving 13 😍 proton machines as a donation to improve access to #radiotherapy. If only we had such philanthropy in Australia!!! 🦘🇦🇺🐨 @SEOR_ESP #simposioSEOR25
6
14
67
📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy) ⬆️ 12-month PFS rate: 72% vs 54% ⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025) 😳 really not “oligo” population! ✅Grade ���3 AEs: 29% (LCT arm) vs 22% (control) #radonc
3
44
102
📢 📢 NORTHSTAR: Phase II Randomized Study of OSI +/- Local Consolidative Therapy for EGFR + NSCLC @YYElamin. First + RCT using 3rd G TKI + LCT (mPFS 25.3 vs 17.5 mo HR 0.66). Nicely discused by @ZPiotrowskaMD. #ESMO25 #ESMOAmbassadors
NORTHSTAR trial at #ESMO2025. Improvement in PFS in EGFR +ve NSCLC with local consolidation (SABR or surgery). Improvement seen in oligo metastatic disease and in some patients with polymetastatic disease. Keeping patients on the most tolerable systemic treatment is meaningful.
0
6
25
I am delighted to share this new review in @NatureCancer that I co-author with @AnqiDong18 In which we discuss the different EMT tumor states and their implications for metastasis and cancer therapy.
NEW content online! Identification, functional insights and therapeutic targeting of EMT tumour states https://t.co/1g5x4td9Vc
0
14
41
📢 New in European Urology: SABR is not just for brain mets. A systematic review shows excellent results in RCC—alone or with IO. 🧠 Local control in primary RCC 🛡️ Delay of systemic therapy in oligomets ⚡ IO + SABR: promising combos 🔗 https://t.co/NFYeh5AUPH
#RCC #SABR
1
45
97
With this being the case, makes it difficult to endorse surgery for any of these stage IA lung cancers. SBRT or ablation is likely more than sufficient. @IPScottOh @IP_DOC @AAB_IP
No role for mediastinal LN dissection in clinical stage T1N0M0 GGO-dominant invasive lung adeno, defined by consolidation-to-tumor ratio (CTR) ≤0.5 & maximum tumor diameter (including solid and GGO components) ≤3 cm. Zero positive hilar nodes in those that were resected!
1
5
25
Excited to be a part of this collaboration with friends and colleagues in Amsterdam. It isn't inspired entirely to advance SABR in place of surgery; instead, it is about identifying how often adrenalectomies end up with positive margins and local recurrence. The preliminary data
4
10
38
🚨NEW in @CACancerJournal: A comprehensive review of advances in hepatocellular carcinoma (#HCC) therapy. From surgery to IR to SBRT to immunotherapy, this is your clinical update 🧵 @NiuSanford @nbn426 @KrishanJethwa @safaviaa @ldawsonmd @aallam_mo @freddyeescorcia @5_utr
Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians @CACancerJournal @michael_lidsky
3
18
35
4ª Masterclass #Radioterapia en Cáncer de Pulmón ➡️Protonterapia: un horizonte al alcance 📆Jueves 22 de mayo ℹ️ https://t.co/5wSOSfCPmH
0
2
3
💥 Moderamos MasterClass sobre Protonterapia en cáncer de pulmón 💥 🎤 Ponentes🔝: 👩⚕️ Dra. @nuria_dios – Santiago de Compostela 🏥 Innovación 👨⚕️ Dr. Jacobo Palma – @ClinicaNavarra ✔️ Indicaciones 👨🔬 Sr. Juan Castro – @quironsalud💡Aspectos físicos Discusor: Dr @OncoRod
#SomosHUVR
0
1
3
Wow, this trial showed no OS benefit to FOLFIRINOX vs. single agent gemcitabine in locally advanced pancreas cancer (different than adjuvant & metastatic trials - both w OS improvement!) PFS increased by 2 mo, but this came at cost of increased toxicity, $, treatment burden.
🚨 NEOPAN - Pancreatic Cancer Update 🚨 In LAPC (locally advanced pancreatic cancer) 🧬: 📊 Trial compared FOLFIRINOX vs Gemcitabine 👥 171 patients, PS ≤1, unresectable cases 📌 Primary endpoint: PFS 📌 Secondary endpoints: OS, QoL, safety 🧪 Results: 🕒 Median PFS: ➡️
8
53
170
[1/5] Buenas noticias para pacientes con #CáncerDePróstata recurrente. Nuestro equipo de Oncología Radioterápica ha participado en el ensayo PEACE V–STORM, recién publicado en The Lancet Oncology. Te contamos por qué es importante. #Oncología #Radonc
@Antoniojconde @HospitalLaFe
1
2
4
Se está celebrando la I Jornada de la Plataforma Interdisciplinar de Investigación Traslacional en Oncología Radioterápica
1
10
21
1/ 🧨 OMET trial (GORTEC 2014-04) in oligometastatic HNSCC 👥 N=69, SABR alone vs SABR + chemo + cetuximab 🧪 Key finding: Similar 1-year OS without ⬇️QoL (SABR 55.2% vs chemo-SABR 53.3%). 🏆SABR alone had⬇️toxicity and QoL impact. 📉 Gr 3–4 tox: 8.8% (SABR alone) vs 60% 🧵
3
50
102
📢 ¡No te pierdas la mesa ASTRO/ESTRO! 🌍🔬 En el 4.º Congreso Iberoamericano: Lo Mejor en Cáncer de Pulmón 2024,destacados expertos @OncoRod @JLLopezGuerra nos presenta los últimos avances en radioterapia para el cáncer de pulmón, moderados por el Dr. Jorge Palazzo. #CLICaP 🫁
0
2
4
Our incredible GI leaders paving the path for EBRT in HCC. Published in @LancetGastroHep “Compelling new randomised controlled trial results support that future hepatocellular carcinoma guidelines should include EBRT”. See figure. @StephDudzinski, you’re a superstar!
4
54
154